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Abstract
Background: Research suggests antihypertensive medications are associated with fractures in older adults, however
results are inconsistent and few have examined how the association varies over time. We sought to examine the
association between antihypertensive class and incident non-vertebral fractures among older adults initiating
monotherapy according to time since initiation.
Methods: We used a new-user cohort design to identify Medicare beneficiaries (≥ 65 years of age) initiating
antihypertensive monotherapy during 2008–2011 using a 20% random sample of Fee-For-Service Medicare
beneficiaries enrolled in parts A (inpatient services), B (outpatient services), and D (prescription medication)
coverage. Starting the day after the initial antihypertensive prescription, we followed beneficiaries for incident
non-vertebral fractures. We used multinomial logistic regression models to estimate propensity scores for
initiating each antihypertensive drug class. Using these propensity scores, we weighted beneficiaries to achieve the
same baseline covariate distribution as beneficiaries initiating with angiotensin-converting enzyme inhibitors. Lastly,
we used weighted Cox proportional hazard models to estimate hazard ratios (HRs) of having an incident fractures
according to antihypertensive class and time since initiation.
Results: During 2008–2011, 122,629 Medicare beneficiaries initiated antihypertensive monotherapy (mean age 75, 61%
women, 86% White). Fracture rates varied according to days since initiation and antihypertensive class. Beneficiaries
initiating with thiazides had the highest fracture rate in the first 14 days following initiation (438 per 10,000 person-years,
95% confidence interval (CI): 294–628; HR: 1.40, 0.78–2.52). However, beneficiaries initiating with calcium channel blockers
had the highest fracture rate during the 15–365 days after initiation (435 per 10,000 person-years, 95% CI: 404–468;
HR: 1.11, 1.00–1.24). Beneficiaries initiating with angiotensin-receptor blockers had the lowest fracture rates during the
initial 14 days (333 per 10,000 person-years, 190–546, HR: 0.92, 0.49–1.75) and during 15–365 days after
initiation (321 per 10,000 person-years, 287–358, HR: 0.96, 0.84–1.09).
Conclusion: The association between antihypertensives and fractures varied according to class and time since
initiation. Results suggest that when deciding upon antihypertensive therapy, clinicians may want to consider possible
fracture risks when choosing between antihypertensive drug classes.
Keywords: Fractures, Older adults, Epidemiology, Antihypertensive initiation
* Correspondence: jjones86@live.unc.edu
1Gillings School of Global Public Health, The University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Hargrove et al. Injury Epidemiology  (2017) 4:27 
DOI 10.1186/s40621-017-0125-8
Background
Fractures are one of the most common fall-related injuries
for adults over the age of 65 (DeGrauw et al. 2016). In
older adults, fractures are associated with high medical
costs, loss of independence, and an increased risk of mor-
tality (Stevens et al. 2006; Leibson et al. 2002; Tinetti and
Williams 1997; Haentjens et al. 2010). Older adults are at
greater risk of fractures due to decreased bone mineral
density (BMD), decreased physical activity, and increased
comorbidities (Marks et al. 2003). Comorbidities such as
cardiovascular disease, osteoporosis, Parkinson’s disease,
and diabetes can increase fracture risk (Woolf and Åkesson
2003; Lee et al. 2015). Medications increasing the risk of
fractures include opioids, benzodiazepines, antidepressants,
antiepileptics, and skeletal muscle relaxants (Fraser et al.
2014; By the American Geriatrics Society 2015 Beers Cri-
teria Update Expert Panel 2015; Takkouche et al. 2007).
Recently, research suggests antihypertensives may increase
the risk of fall-related injury by as much as 11% among
older adults (Butt and Harvey 2015; Tinetti et al. 2014).
Antihypertensives are associated with fractures through
medication-related adverse events and by interactions
with BMD (Berry and Kiel 2014). In the first few weeks
after initiation, antihypertensives can increase the risk of
falls and subsequent fractures due to medication-related
adverse events, such as orthostatic hypotension (Butt and
Harvey 2015; Zia et al. 2015). Orthostatic hypotension is
defined as a decrease in blood pressure upon standing
(Gupta and Lipsitz 2007), and is associated with an ele-
vated risk of falls and fractures among hypertensive adults
(Gangavati et al. 2011). Additionally, antihypertensives
have been found to impact BMD in observational and
clinical studies. For instance, thiazide diuretics reduce
urinary calcium secretion and can stimulate osteo-
blasts potentially providing a protective effect for
fractures (Ghosh and Majumdar 2014; Ruths et al.
2015; Solomon et al. 2011). Angiotensin-receptor
blockers and angiotensin-converting enzyme inhibitors
are believed to impact BMD by inhibiting bone turn-
over caused by the renin-angiotensin-aldosterone sys-
tem (Ghosh and Majumdar 2014).
Prior research has found inconsistent results regarding
the strength and direction of the association between an-
tihypertensives and fractures (Butt and Harvey 2015;
Zang 2013). Some studies have found antihypertensives
increase the risk of fractures (Tinetti et al. 2014;
Choi et al. 2015; Butt et al. 2012), while others have
found no association (Fraser et al. 2014), or a pro-
tective association with fractures (Ruths et al. 2015;
Solomon et al. 2011; Rejnmark et al. 2006). Few
studies have examined the initial increased risk of
fractures associated with starting antihypertensive
therapy, and how the association between antihyper-
tensives and fractures varies time. Therefore, we
sought to examine the association between antihyper-
tensives and incident non-vertebral fractures within
the first year of initiation among Medicare beneficiar-
ies. Specifically, we hypothesized that fractures in the
first 2 weeks would be due to medication-related ad-
verse events and fractures that occurred between
2 weeks and 1 year of use would be due to possible
BMD effects.
Methods
Data source
We used a 20% nationwide, random sample of fee-for-
service Medicare beneficiaries who were enrolled at
least 1 month in Medicare Parts A (inpatient care), B
(outpatient care), and D (prescription drugs) coverage be-
tween 2007 and 2011. Data were obtained under a data
use agreement established with the Centers for Medicaid
and Medicare Services (CMS) and the University of North
Carolina at Chapel Hill (UNC-CH). The study protocol
was approved by UNC’s Non-Biomedical Institutional
Review Board.
New users of antihypertensive monotherapy
The study cohort consisted of all new users of antihy-
pertensive medication initiating during 2008–2011
who were continuously enrolled in Medicare Parts A,
B, and D for at least 12 months prior to initiation. New
use was defined as not having a prior prescription of
the following antihypertensive medications in the last
12 months: angiotensin-converting enzyme inhibitors
(ACE), angiotensin-receptor blockers (ARB), beta
blockers (BB), calcium channel blockers (CCB), or
thiazide diuretics (THZ). We limited the cohort to
beneficiaries initiating with monotherapy (e.g., one
class of antihypertensive drug) since we were inter-
ested in examining differences in effect by drug class.
Loop diuretics were excluded from the exposure
definition since these drugs are typically prescribed for
different indications and are a marker of increased short-
term mortality in to older adults (Glynn et al. 2001).
We excluded beneficiaries who were originally eligible
for Medicare due to end stage renal disease or disability
and those beneficiaries with prior nursing home stays
since not all medications dispensed in the nursing home
are captured in Part D data. Additionally, we excluded
beneficiaries who had a previous diagnoses for tremors
or congestive heart failure since these health conditions
could result in being prescribed antihypertensives. Since
we were interested in capturing incident fractures and
since prior falls can increase future fall and fracture risk
(Pohl et al. 2014), we excluded beneficiaries who had
prior falls or fractures. Finally, we required a second an-
tihypertensive fill within 30 days of the end of the
index drug’s days supply to exclude those beneficiaries
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who filled the first prescription and never returned
(Additional file 1: Figure S1). We did not exclude
beneficiaries with chronic kidney disease or diabetes,
despite these being indications for certain antihyper-
tensive drug classes, however we did conduct sub-
analyses excluding these beneficiaries (see Statistical
Analysis).
Initiation of antihypertensive therapy
Prescription medication data were identified using Medi-
care Part D. Using fill dates, we identified the date of the
initial prescription for antihypertensive therapy (index
date). Antihypertensive medications were identified
using National Drug Codes and generic drug names
(Additional file 1: Table S1). These specific drug classes
were chosen based on the current recommendations for
hypertension treatment in older adults (James et al. 2014).
Incident non-vertebral fractures
Incident non-vertebral fractures within 12 months of initi-
ating antihypertensive monotherapy were our primary out-
come. Starting the day after the index date, we followed
beneficiaries until the first fracture event. Fractures were
identified using validated diagnostic and procedure codes
in Medicare Parts A and B (Additional file 1: Table S2)
(Ray et al. 1992). We chose to examine fractures instead of
falls since the accuracy of fall reporting varies by state and
has low specificity in claims data (Annest et al. 2008). We
excluded fractures that had a corresponding external
cause-of-injury relating to motor vehicle crashes (E810-
E825) and those that occurred on the index date.
In sub-analyses, we grouped fractures according to the
anatomical location to distinguish between fractures that
were likely related to low BMD. Low BMD fractures, or
osteoporotic fractures, are typically defined as fractures
occurring at the hip, radius, or vertebrae (Johnell and
Kanis 2005). Since incident vertebral fractures are not
well captured in claims data (Curtis et al. 2009), we de-
fined probable low BMD fractures as any fracture event
involving the hip or radius. All other non-vertebral frac-
tures were classified as probable normal BMD fractures.
Risk factors for fractures
Covariates were selected based on the previous literature
(Woolf and Åkesson 2003; Lee et al. 2015; By the Ameri-
can Geriatrics Society 2015 Beers Criteria Update Expert
Panel 2015; Zia et al. 2015; Nurminen et al. 2013) and
were defined based on claims during the 12 months
prior to initiation (Additional file 1: Table S3). Covari-
ates included: demographics (age, gender, and race), con-
current medication use and prior use of medications
associated with fractures (loop diuretics, antiarrhyth-
mics, antidepressants, antiepileptics, anxiolytics, benzo-
diazepines, bisphosphonates, antipsychotics, skeletal
muscle relaxants, opioids, and hypnotics), codes for
chronic comorbidities associated with fracture risk (dia-
betes, chronic kidney disease, Parkinson’s disease, Alz-
heimer’s disease, osteoporosis, arrhythmia, osteoarthritis,
rheumatoid arthritis, stroke, myocardial infarction,
hypertension, orthostatic hypotension, syncope, demen-
tia, urinary incontinence, dyslipidemia, and obesity),
frailty predictors, and prior hospital admissions. Concur-
rent medication use was defined as the number of dis-
tinct drug prescriptions filled in the 14 days prior to
antihypertensive initiation. As a proxy for sociodemo-
graphic status, we identified whether beneficiaries were
eligible for the Medicare low-income subsidy (LIS) pro-
gram. LIS offers medication at a reduced cost for benefi-
ciaries that are eligible due to income, family size, and
household resources. We included the frailty index score
as a proxy measure of frailty (Faurot et al. 2015). Add-
itionally, we examined the prevalence of factors posi-
tively (ambulance transfer, wheelchair/walker use, home
oxygen use, hospital bed, difficulty walking, and vertigo)
and inversely (cancer screenings) associated with limita-
tions in activities of daily living (Faurot et al. 2015).
Statistical analysis
Descriptive statistics were used to compare baseline co-
variates according to antihypertensive class initiated on
the index date. We estimated propensity scores (PS)
using multinomial logistic regression models. PSs esti-
mated the probability of receiving an ACE vs. other clas-
ses of antihypertensive drugs adjusting for all baseline
covariates. Standardized mortality ratio (SMR) weighting
was used to control for confounding due to differences
in propensity scores. We weighed beneficiaries of each
drug class to achieve the same baseline covariate distri-
bution as beneficiaries receiving an ACE. Therefore,
beneficiaries initiating with ACEs were assigned a weight
of one and all others were assigned a weight that was
the ratio of the PS to one minus the PS (Stürmer et al.
2006). ACEs were used as the referent since they were
the most commonly prescribed drug class (Li et al.
2014). To examine the effectiveness of PSs and SMR
weights to correctly balance baseline covariates between
beneficiaries, we examined the means and proportions
of baseline covariates before vs. after SMR weighting. If
the PSs are correctly specified, there should be little dif-
ference between the mean and proportion of baseline
covariates across antihypertenisves classes.
Incident fracture rates and corresponding 95% confi-
dence intervals (CIs) were defined as the total number
of incident fractures by the total person-years at risk.
Person-years at risk was defined as the total number of
days at risk for fractures divided by 365.25. To account
for censoring, we used SMR-weighted Cox proportional
hazard models to estimate hazard ratios (HRs) and 95%
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CIs of incident fractures for each drug class initiated on
the index date versus receiving an ACE according to
days since initiation of therapy, 1–14 days and 15–
365 days. We separated time since initiation to distin-
guish between fractures likely related orthostatis and
fractures that may be the result of possible BMD effects.
CIs were calculated using robust standard errors to ac-
count for SMR weights. We used a ‘first-treatment-car-
ried-forward’ analysis to avoid introducing confounding
by indication since antihypertensive adherence varies,
and beneficiaries who remain adherent may differ from
the majority of hypertensive patients (Hargrove et al.
2017). Using this analysis, beneficiaries contributed
person-time at risk until they had an incident fracture or
until the end of the follow-up (death, disenrollment from
Medicare, or December 31, 2012), whichever came first.
SMR weighted Kaplan-Meier curves were used to graph
the proportion of beneficiaries without fracture events
according to time since initiation. For our secondary
analysis when we classified fractures according to prob-
able low vs. normal BMD fractures, if a beneficiary had a
fracture event before the event of interest (e.g., normal
BMD fracture before a low BMD fracture), beneficiaries
were censored at the date of the first fracture event.
Sensitivity analyses
To assess the robustness of our analysis decisions, we
performed sensitivity analyses. First, we repeated the
analysis using an ‘As-treated’ analysis design. In the ‘As-
treated’ analysis, follow-up additionally ended when
beneficiaries switched antihypertensive therapy (e.g.,
switched to another antihypertensive class or started
combination therapy), or discontinued use (e.g., failed to
fill another prescription 30 days after the end of the last
drugs’ days supply). Second, we repeated the analysis ex-
tending the first follow-up period to 30 days since the
time it takes for blood pressure to stabilize after antihy-
pertensive initiation is not known. Third, we repeated
the primary analysis excluding beneficiaries who initiated
therapy using a brand antihypertensive medication ver-
sus a generic antihypertensive medication. Generic med-
ications are less prone to sample use and are thus less
prone to have started antihypertensive therapy before
the first dispensed prescription (Hampp et al. 2016).
Fourth, since chronic kidney disease and diabetes can
impact physicians’ choice of antihypertensive class pre-
scribed, we repeated the analysis removing any benefi-
ciaries with these chronic conditions. Lastly, we repeated
the analysis removing beneficiaries prescribed loop di-
uretics during the baseline period since these medica-
tions may be a marker for overall worse health and
greater risk of morality (Glynn et al. 2001).
All statistical analyses were conducted using SAS Ver-
sion 9.4 (Cary, NC).
Results
Between 2008 and 2011, 122,629 Medicare beneficiaries
initiated antihypertensive monotherapy. On average
beneficiaries were 75 years old, 61% were women, and
the majority were White (86%). The most common clas-
ses of antihypertensives prescribed were ACEs (33%),
BBs (30%), and CCBs (15%). Before SMR weighting,
demographics, diabetes, chronic kidney disease, cardio-
vascular disease (e.g., arrhythmia, stroke, hypertension,
and dyslipidemia), ambulance transfers, cancer screen-
ings, and prior hospitalizations differed across benefi-
ciaries according to antihypertensive class. After SMR
weighting, there was little difference between baseline
characteristics according to antihypertensive class
(Table 1).
During the first year after initiation of antihypertensive
monotherapy, beneficiaries experienced 4430 incident
non-vertebral fractures over 115,991 person-years
(rate = 382 per 10,000 person-years, 95%CI: 371–393).
Fractures most commonly occurred at the hip (79%),
foot (17%), radius (15%), and hand (14%). Just over
three-quarters of fractures resulted in a single-bone
break (77%).
Rates of incident fracture varied according to antihy-
pertensive class and by time since initiation (Table 2,
Additional file 1: Figure S2). During the first 14 days,
beneficiaries who initiated with THZs (438 per 10,000
person-years, 95%CI: 294–628) and BBs (410 per 10,000
person-years, 95%CI: 314–526) had the highest rate of
fractures. Beneficiaries initiating with CCBs had the
highest rate of fractures during the 15–365 days after
initiation (435 per 10,000 person-years, 95%CI: 404–
468), but a low rate in the first 14 days (383 per 10,000
person-years, 95%CI: 258–550). Initiators of ARBs had
the lowest rate of fractures during the initial 14 days
(333 per 10,000 person-years, 95%CI: 190–546) and dur-
ing the 15–365 days after initiation (321 per 10,000
person-years, 95%CI: 287–358).
After controlling for differences in baseline character-
istics, beneficiaries who initiated with THZs had the
highest rate of fractures in the first 14 days after initi-
ation compared to beneficiaries who initiated with ACEs
(SMR-HR: 1.40, 95%CI: 0.78–2.52). After the first
14 days, beneficiaries who initiated with CCBs (SMR-
HR: 1.11, 95%CI: 1.00–1.24) and BBs (SMR-HR: 1.09,
95% CI: 1.00–1.19) had slightly higher fractures rates
compared to the beneficiaries who initiated with ACEs.
When we stratified results according to fracture loca-
tion (probable low BMD fractures vs. normal BMD frac-
tures), results were similar for all the antihypertensive
classes except THZs (Table 3). During the 1 year follow-
ing initiation, beneficiaries who initiated with THZs had
a lower hazard ratio of probable low BMD fractures
(SMR-HR: 0.85, 95%CI: 0.68–1.06), but a slightly higher
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Table 1 Characteristics of Medicare beneficiaries initiating antihypertensive monotherapy between 2008 and 2011 (n = 122,629)
ACE
n = 40,186
ARB
n = 10,954
BB
n = 36,972
CCB
n = 18,411
THZ
n = 16,106
Cohort Cohort SMRW Cohort SMRW Cohort SMRW Cohort SMRW
Mean Age, std. (years) 74, 6.7 75, 6.7 74, 12.9 75, 7.0 74, 7.1 76, 7.4 75, 10.0 75, 7.0 75, 10.8
Mean Frailty Index, std 0.1, 0.1 0.1, 0.1 0.1, 0.2 0.1, 0.1 0.1, 0.1 0.1, 0.2 0.1, 0.2 0.1, 0.1 0.1, 0.2
Male 42.0 36.6 41.5 41.7 42.2 37.8 42.1 29.3 42.4
White Race 87.1 79.0 87.3 88.8 86.9 81.8 86.9 86.5 87.2
Low-Income Subsidy 5.3 5.5 5.5 4.6 5.4 5.8 5.4 5.0 5.2
1–2 Meds Filleda 61.3 62.4 61.8 58.6 61.4 59.8 62.5 66.9 62.5
3–4 Meds Filleda 27.7 26.5 27.4 28.7 27.2 27.1 26.3 24.7 26.5
5 + Meds Filleda 11.1 11.2 10.8 12.7 11.4 13.0 11.3 8.5 11.1
Loop Diuretic 5.8 5.9 5.9 7.0 6.1 6.4 6.0 3.7 6.4
Antiarrhythmic 2.6 4.2 2.5 5.4 2.8 4.5 2.7 2.7 3.0
Antidepressantb 15.2 14.9 15.2 16.0 15.6 15.9 15.6 15.4 15.5
Antipilepticb 7.4 7.3 7.3 8.0 7.5 8.2 7.6 7.7 7.4
Anxiolytic 3.4 3.4 3.5 4.0 3.6 4.1 3.6 3.7 3.5
Benzodiazpeneb 1.1 1.0 1.1 1.4 1.2 1.3 1.2 1.3 1.1
Bisphosphonate 10.6 12.4 10.6 11.2 10.4 11.6 10.7 13.0 10.8
Antipsychoticb 3.5 2.8 3.5 4.2 3.7 4.9 3.7 3.8 3.7
Skeletal Muscle Relaxantb 6.2 6.2 6.2 6.5 6.5 6.3 6.4 6.5 6.4
Opioid 27.0 26.2 27.4 30.2 27.2 29.5 27.5 28.0 28.2
Hypnoticb 6.1 7.9 6.0 7.5 6.1 7.1 6.2 6.7 6.2
Diabetes 31.6 30.6 31.0 19.0 32.8 18.3 31.4 13.5 32.9
Chronic Kidney Disease 8.7 10.5 8.8 10.6 9.4 13.1 9.3 6.3 9.8
Parkinson’s Disease 1.2 1.1 1.2 1.5 1.2 1.5 1.2 1.3 1.2
Alzheimer’s Disease 3.2 2.4 3.1 3.0 3.4 4.4 3.3 3.1 3.6
Osteoporosis 14.1 17.3 14.2 16.0 14.1 17.4 14.4 16.9 14.6
Arrhythmia 10.5 10.9 10.4 32.9 10.6 25.4 10.6 8.5 11.6
Osteoarthritis 14.4 17.8 14.3 16.1 14.7 15.5 14.9 15.7 15.1
Rheumatoid Arthritis 2.5 3.4 2.5 3.2 2.6 3.0 2.7 2.5 2.6
Stroke 13.7 13.5 13.5 16.6 15.0 16.4 15.1 10.3 14.9
Myocardial Infarction 0.6 0.2 0.6 4.0 0.6 0.6 0.7 0.1 0.7
Hypertension 83.3 88.2 83.5 63.3 84.3 78.6 85.3 76.8 85.0
Orthostatic Hypotension 0.6 0.6 0.7 1.1 0.7 0.9 0.8 0.5 0.6
Syncope 3.8 4.2 3.7 7.4 4.0 6.1 4.2 3.0 4.3
Dementia 5.8 4.2 5.6 5.9 6.1 8.2 6.1 5.6 6.1
Urinary Incontinence 4.7 4.8 4.7 4.9 4.8 5.5 4.9 4.5 4.9
Dyslipidemia 64.8 70.2 64.2 64.0 65.7 58.2 65.3 57.2 65.3
Obesity 4.4 4.2 4.5 3.6 4.6 3.3 4.4 4.1 4.4
Home Oxygen Use 2.4 2.5 2.4 2.5 2.6 5.3 2.3 2.7 2.6
Walker/Wheelchair Use 2.2 2.4 2.2 2.8 2.3 3.3 2.3 2.4 2.5
Hospital Bed Use 0.5 0.5 0.5 0.5 0.5 0.9 0.5 0.5 0.6
Difficulty Walking 7.7 7.5 7.6 8.8 8.2 9.5 8.4 8.2 8.3
Vertigo 11.5 12.4 11.3 14.5 12.1 14.1 12.4 12.4 12.1
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hazard ratio of normal BMD fractures (SMR-HR: 1.12,
95%CI: 0.98–1.29) compared to beneficiaries who initi-
ated with ACEs.
In sensitivity analyses, results were similar when we 1)
used an ‘as-treated’ analysis, 2) excluded beneficiaries
with a previous diagnosis of chronic kidney disease or
diabetes, and 3) excluded beneficiaries who initiated with
brand antihypertensive drugs (Fig. 1, Additional file 1:
Table S4). When we extended the initial follow-up
period to 30 days, beneficiaries who initiated with THZs
(SMR-HR: 1.15, 95%CI: 0.75–1.76) and BBs (SMR-HR:
1.36, 95%CI: 1.01–1.83) still had the highest rate of frac-
tures compared to beneficiaries who initiated with other
antihypertensive classes (results not shown).
Discussion
We found incident fracture rates in the year following
initiation of antihypertensive therapy differ depending
on antihypertensive class, and these patterns were af-
fected by the time since initiation. Medicare beneficiaries
who initiated with THZs or BBs had slightly higher frac-
ture rates during the first 2 weeks compared to benefi-
ciaries who initiated with other antihypertensives.
However, during the first year beneficiaries who initiated
with CCBs had the highest fracture rate. Similar to pre-
vious research, we found beneficiaries who initiated with
ACEs or ARBs had the lowest rate of fractures (Butt and
Harvey 2015; Choi et al. 2015; Wong et al. 2013).
We found older adults initiating with THZs or BBs
had the highest fracture rates during the first 2 weeks
following initiation. Similar to our results, Berry et al.
found that THZ initiators had an increased odds of hip
fracture in the first days following initiation compared to
periods of no use (Berry et al. 2013). Butt et al. found
that the use of any antihypertensive was associated with
an increased risk of hip fracture in the first 45 days fol-
lowing initiation, and that this risk was most elevated for
older adults initiating with ACEs (Butt et al. 2012). How-
ever, Ruths et al. found that only loop diuretics were as-
sociated with an initial increased risk of hip fractures
during the first 2 weeks of use when comparing the ini-
tial fracture risk among antihypertensive class (Ruths et
al. 2015). This initial increase in fracture rates may be
due to orthostatic hypotension. Among the classes of an-
tihypertensives, THZs are most strongly associated with
orthostatic hypotension (Zia et al. 2015). Given that
Table 1 Characteristics of Medicare beneficiaries initiating antihypertensive monotherapy between 2008 and 2011 (n = 122,629)
(Continued)
ACE
n = 40,186
ARB
n = 10,954
BB
n = 36,972
CCB
n = 18,411
THZ
n = 16,106
Cohort Cohort SMRW Cohort SMRW Cohort SMRW Cohort SMRW
Ambulance Transport 6.9 4.7 6.8 12.4 7.3 12.5 7.3 5.4 7.5
Cancer Screenings 41.0 39.2 40.9 39.3 40.4 35.5 40.6 43.6 40.1
Hospital Admissions 13.2 10.1 13.2 25.5 13.6 23.8 13.4 10.0 14.3
aNumber of number of distinct drug prescriptions filled in the 14 days prior to antihypertensive initiation
bMedication indicated to be associated with fracture risk according to the 2015 Beers Medication Guideline (By the American Geriatrics Society 2015 Beers Criteria
Update Expert Panel 2015)
Prevalence of baseline characteristics was identified 12 months prior to initiation of antihypertensive monotherapy
Race was missing for a total of 147 beneficiaries and these were excluded from the SMR weighted analysis
Standardized mortality ratio weighting (SMRW) was used to weight beneficiaries of each drug class to achieve the same baseline covariate distribution as
beneficiaries receiving an ACE. Beneficiaries initiating with ACEs were assigned a weight of 1 and all others were assigned a weight that was the ratio of the
propensity score to 1 minus the propensity score
ACE Angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BB beta blockers, CCB calcium channel blockers, or THZ thiazide diuretics
Table 2 Rates and hazard ratios of incident fractures within the first year of initiating antihypertensive monotherapy
Drug
Class
1–14 days after initiation 15–365 days after initiation
# Fractures P-Yrs Rate Per 10,000
P-Yrs (95% CI)
SMRW HR (95% CI) # Fractures P-Yrs Rate Per 10,000
P-Yrs (95% CI)
SMRW HR
(95% CI)
ACE 54 1539 351 (266, 454) ref 1271 36,618 347 (328, 367) ref
ARB 14 420 333 (190, 546) 0.92 (0.49, 1.75) 322 10,032 321 (287, 358) 0.96 (0.84, 1.09)
BB 58 1416 410 (314, 526) 1.00 (0.65, 1.54) 1375 33,449 411 (390, 433) 1.09 (1.00, 1.19)
CCB 27 705 383 (258, 550) 0.82 (0.50, 1.36) 720 16,540 435 (404, 468) 1.11 (1.00, 1.24)
THZ 27 617 438 (294, 628) 1.40 (0.78, 2.52) 562 14,656 384 (353, 416) 1.02 (0.90, 1.15)
P-Yrs person-years (calculated by dividing the total number of follow-up days by 365.25)
SMRW Standardized mortality ratio weight, calculated adjusting for all baseline covariates
Incident fracture rates and corresponding 95% CIs were defined as the total number of incident fractures by the total P-Yrs at risk. Hazard ratios (HRs) and 95%
confidence intervals (CIs) were calculated using SMR weighted Cox proportional hazard models using a ‘first-treatment-carried-forward’ analysis design. CIs were
calculated using robust standard errors to account for the SMRWs
ACE Angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BB beta blockers, CCB calcium channel blockers, or THZ thiazide diuretics
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orthostatic hypotension can be asymptomatic (Butt and
Harvey 2015; Gupta 2012), results suggest that clinicians
and older adults need to be aware of this potential in-
creased risk of fractures when starting antihypertensive
therapy, especially when starting therapy with THZs.
Gangavati et al. found that the risk of falls associated
with orthostatic hypotension was lower among older
adults with controlled hypertension compared to older
adults with uncontrolled hypertension (Gangavati et al.
2011). This suggests that increases in fracture rates once
hypertension is controlled may be due to other mecha-
nisms besides orthostatic hypotension. One mechanism
that may influence the association between antihyperten-
sives and fractures could be antihypertensives interactions
with BMD (Berry and Kiel 2014; Ghosh and Majumdar
2014). We found older adults initiating with THZs had a
decreased rate of probable low BMD (hip and radius) frac-
tures in the year following initiation. THZs can impact the
risk of low BMD fractures by promoting osteoblast activity
and reducing calcium urinary excretion (Ghosh and
Majumdar 2014; Aung and Htay 2011). A 2011 Cochrane
review found that THZs were associated with as much as
a 24% reduction in hip fractures when comparing THZ
users vs. non-users (Aung and Htay 2011). Results suggest
older adults at elevated risk of fractures may potentially
benefit from receiving THZs compared to other classes of
antihypertensives. However, research featuring clinical
BMD measurements is needed to confirm these findings.
Older adults initiating with CCBs had slightly elevated
fracture rates compared with ACE initiators. Previous stud-
ies have found inconsistent results regarding the association
between CCBs and fractures. Ruths et al. found that CCBs
were associated with a decreased risk of hip fractures when
comparing periods of use and non-use (Ruths et al. 2015).
However, this study was limited to hip fractures and results
were unadjusted for comorbidities associated with fractures
(Ruths et al. 2015). In another study, Choi et al. found that
compared to non-users of antihypertensives, adults pre-
scribed CCBs had a slightly elevated rate of non-vertebral
fractures (Choi et al. 2015). In our study, beneficiaries who
initiated with CCBs were frailer than beneficiaries who initi-
ated with other antihypertensives. Although we included
Table 3 Rates of probable low and normal bone mineral density fractures within 1 year of initiating antihypertensive monotherapy
Drug
Class
Probable Low Bone Mineral Density Fractures Normal Bone Mineral Density Fractures
# Fractures P-Yrs Rate Per 10,000
P-Yrs (95% CI)
SMRW HR (95% CI) # Fractures P-Yrs Rate Per 10,000
P-Yrs (95% CI)
SMRW HR
(95% CI)
ACE 424 38,157 111 (101, 122) ref 901 38,157 236 (221, 252) ref
ARB 99 10,452 95 (77, 115) 0.93 (0.74, 1.17) 237 10,452 227 (199, 257) 0.97 (0.84, 1.13)
BB 464 34,864 133 (121, 146) 1.08 (0.93, 1.26) 969 34,864 278 (261, 296) 1.09 (0.98, 1.21)
CCB 280 17,245 162 (144, 182) 1.13 (0.95, 1.35) 467 17,245 271 (274, 296) 1.09 (0.96, 1.24)
THZ 171 15,273 112 (96, 130) 0.85 (0.68, 1.06) 418 15,273 274 (248, 301) 1.12 (0.98, 1.29)
P-Yrs person-years (calculated by dividing the total number of follow-up days by 365.25)
SMRW Standardized mortality ratio weight, calculated adjusting for all baseline covariates
Incident fracture rates and corresponding 95% CIs were defined as the total number of incident fractures by the total P-Yrs at risk. Hazard ratios (HRs) and 95%
confidence intervals (CIs) were calculated using SMR weighted Cox proportional hazard models using a ‘first-treatment-carried-forward’ analysis design. CIs were
calculated using robust standard errors to account for the SMRWs”
Probable low bone mineral density fractures included hip and radius fractures. All other non-vertebral fractures were defined as normal bone mineral
density fractures
ACE Angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BB beta blockers, CCB calcium channel blockers, or THZ thiazide diuretics
Fig. 1 Results of sensitivity analyses comparing the rates of incident fractures according to antihypertensive class. The reference group for the
standardized mortality ratio (SMR) weights was beneficiaries who initiated with angiotensin converting enzyme inhibitors
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frailty predictors in the propensity scores, we cannot elimin-
ate the possibility that residual confounding remained after
adjustment, given that frailty is multi-dimensional and is
difficult to capture with claims data alone (Fried et al. 2004).
Despite conducting sensitivity analyses, this study does
have limitations. First, results may be subject to residual
confounding. We used SMR weights to limit confounding
by indication but it is possible that residual confounding
remained due to physical activity, visual impairment, base-
line BMD, and alcohol use. Some research suggests re-
moving outlier SMR weights to better control for residual
confounding. However, we did not exclude outlier SMR
weights since excluding these observations resulted in lit-
tle difference in the results, suggesting that variations in
weights were most likely random. Second, fracture effects
observed in our study may have been influenced by other
factors such as concurrent medication use, other chronic
conditions, or previously undiagnosed hypertension. How-
ever, results remained the same in sensitivity analyses ex-
cluding beneficiaries with diabetes, chronic kidney disease,
and those previously taking loop diuretics suggesting that
any residual confounding due to side effects from other
chronic conditions or medications is minimal. We were
unable to distinguish between newly diagnosed hyperten-
sion vs. uncontrolled hypertension treated for the first
time using claims data. It is possible that beneficiaries
were at elevated risk of fracture due to uncontrolled
hypertension prior to starting antihypertensive medica-
tion. Third, despite controlling for race in propensity
scores, it is likely that we were unable to control for all
possible race/ethnicity effects due to limitations in the
Medicare race/ethnicity data (McBean 2004). Given that
the majority of our study population was White, more re-
search is needed featuring more diverse ethnic/racial
population to see if the same results would hold true
across racial populations. Fourth, our results are limited to
the 1 year period following initiation and only included
older adults initiating antihypertensives between 2008 and
2011. Antihypertensives impact BMD in as little as 5–
8 weeks in animal studies (Birocale et al. 2016; Kang et al.
2013), however less is known about the time it takes for
antihypertensives to have clinical BMD effects in humans
(Ghosh and Majumdar 2014). One year may not have
been long enough to identify all possible BMD affects.
Additionally, it is possible that since the time of our study
new hypertensive medications have been added to the in-
dividual drug classes, however the overall effects of the
drug classes would likely remain unchanged. Lastly, our
results did not take into account antihypertensive dose.
Previous research suggests that the relationship between
antihypertensives and fractures is linearly associated with
increasing dose (Butt and Harvey 2015; Lipsitz et al.
2015). Results may be underestimated for older adults on
higher doses of antihypertensives.
Conclusions
It is important that researchers and clinicians identify
modifiable factors that may reduce the risk of fractures
among older adults. We found certain classes of antihy-
pertensive medications may impact the rate of fractures
in older adults. Specifically, we found slightly increased
fracture rates among older adults initiating with THZs
and BBs during the first 2 weeks after initiation. Results
suggest older adults taking these medications should be
aware of this possible increased risk of fractures, particu-
larly in the first few weeks after starting therapy. Also,
we found older adults initiating with ACEs and ARBs
had slightly lower fracture rates after initiation. However,
given that our results may be due to chance variation in
effects, more research is needed to verify if these same
results hold true across various racial/ethnic populations
and across longer periods of follow-up. Results suggest
that when deciding upon antihypertensive therapy, clini-
cians may want to consider possible fracture risks when
choosing between antihypertensive drug classes.
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